首页> 外文OA文献 >A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole

【2h】

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole

机译：afatinib是一种不可逆的ErbB家族阻滞剂的II期研究，已在来曲唑治疗的雌激素受体阳性激素难治性转移性乳腺癌患者中加入来曲唑

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Katharina Gunzer; Florence Joly; Jean-Marc Ferrero; Joseph Gligorov; Helene de Mont-Serrat; Martina Uttenreuther-Fischer; Katy Pelling; Sven Wind; Guilhem Bousquet; Jean-Louis Misset;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab [J] . LinN.U., WinerE.P., WheatleyD., Breast cancer research and treatment. . 2012,第3期

机译：afatinib（BIBW 2992）（一种不可逆的ErbB家族阻滞剂）在HER2阳性转移性乳腺癌患者曲妥珠单抗治疗后进展的II期研究
2. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab [J] . Nancy U. Lin, Eric P. Winer, Duncan Wheatley, Breast Cancer Research and Treatment . 2012,第3期

机译：afatinib（BIBW 2992），一种不可逆的ErbB家族阻滞剂，在曲妥珠单抗后进展为HER2阳性转移性乳腺癌的患者中进行II期研究
3. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. [J] . Baselga J, Semiglazov V, van Dam P, Journal of Clinical Oncology . 2009,第16期

机译：雌激素受体阳性乳腺癌患者新辅助依维莫司加来曲唑与安慰剂加来曲唑比较的II期随机研究。
4. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. A phase II study of afatinib an irreversible ErbB family blocker added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole [O] . Katharina Gunzer, Florence Joly, Jean-Marc Ferrero, -1

机译：afatinib是一种不可逆的ErbB家族阻滞剂的II期研究已在来曲唑治疗的雌激素受体阳性激素难治性转移性乳腺癌患者中加入来曲唑
7. A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole [O] . Gunzer, Katharina, Joly, Florence, Ferrero, Jean-Marc, 2016

机译：afatinib是一种不可逆的ErbB家族阻滞剂的II期研究，已在来曲唑治疗的雌激素受体阳性激素难治性转移性乳腺癌患者中加入来曲唑

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole

著录项

引文网络

相似文献

相关主题

期刊订阅